2 Mid-Cap Biotech Stocks to Buy Right Now
Generally speaking, biotech stocks were one of the best places to put your money in 2019. The iShares Nasdaq Biotechnology ETF gained a stellar 25.2% last year, despite the political wrangling over prescription drug prices in the United States. Fortunately, this upward trend should continue unabated in 2020. The biotech industry, after all, has been generating game-changing breakthroughs across a number of areas in recent years, opening up a wide range of novel, high-value markets.
Where should cautious investors put their money in the diverse landscape that is biotech? Mid-cap biotechs -- or companies with market caps of between $2 billion to $10 billion -- tend to offer a compelling mix of upside potential and relative safety for individuals that like to avoid hefty doses of risk. The fundamental reason is that biotechs with modest market caps generally have at least one approved product on the market, stable and growing free cash flows, and assets that may attract a larger partner.
Image source: Getty Images.
Source Fool.com
